Special Issue "Stem Cell Engineering: From Reprogramming Technologies to Translational Biomedicines"
A special issue of Biomedicines (ISSN 2227-9059).
Deadline for manuscript submissions: closed (31 October 2016).
Interests: stem cell biology; regenerative medicine; neuroscience; glia; oligodendrocyte; astrocyte; microglia
Special Issues and Collections in MDPI journals
This Special Issue will explore both previously unappreciated mechanisms of stem cell reprogramming and differentiation, and new strategies of translating fundamental insights into discovery of new therapies. The scope of this Special Issue includes cell engineering-based disease modeling, stem cell-based drug discovery, and prospects for applying unique aspects of tissue engineering in stem cells for regenerative medicine. We are seeking contributions from leading investigators and experts who are interested in reprogramming somatic cells to pluripotent stem cells, characterizing cell lineages and precursor populations and identifying key factors that influence growth/expansion of stem cells (e.g., DNA repair proteins and miRNAs), developing genetic or chemical platforms to reprogram or engineer cell fate and to control cell differentiation, with interdisciplinary approaches focused on early stage translational research to develop novel therapeutic approaches to address unmet medical needs. In particular, we welcome contributions on cell engineering with therapeutic applications, e.g., in vivo mouse lineage tracing models and in vitro near-physiological organoid culture methods to characterize stem/progenitor cell populations and to assess roles of mutant stem/progenitor cells in tumors, on the one hand, to harness the regenerative capacity of normal stem cells for therapeutic use, and on the other hand, to develop ways of blocking cancer-promoting activities of mutant stem cells. We hope this Special Issue will provide the most accessible and current contents of the key points and concepts in the field, and that researchers in the field will find these cutting-edge original research papers and in-depth review articles to be useful. Topics include:
• Genetic or epigenetic regulation of stem cell fate
• Transcriptional regulation or chemical modulation of stem cell fate
• Stem cell technology, 3D organoid culture, genome editing, CRISPR/Cas9 system, bioengineering, and cell-material interaction
• Cancer stem cells, cancer epigenetics, cancer metabolism, and 3D modeling of cancer using human iPSC
Dr. Wenbin Deng
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- in vitro reprogramming
- direct reprogramming
- stem cell fate
- stem cell niche
- cancer stem cell
- small-molecule stem cell modulators
- 3D organoid bioengineering
- regulatory RNAs
- stem cell medicine